A phase II multicenter trial assessing the efficacy and safety of first-line S-1 + ramucirumab in elderly patients with advanced/recurrent gastric cancer: KSCC1701

Kazuma Kobayshi,Koichi Suyama,Hiroo Katsuya,Naoki Izawa,Yoshikazu Uenosono,Qingjiang Hu,Tetsuya Kusumoto,Hajime Otsu,Hiroyuki Orita,Hirofumi Kawanaka,Kazunori Shibao,Satoshi Koga,Mototsugu Shimokawa,Akitaka Makiyama,Hiroshi Saeki,Eiji Oki,Hideo Baba,Masaki Mori

European Journal of Cancer（2022）

引用 2|浏览9

暂无评分

摘要

•Elderly ARGC patients with good performance status were enrolled.•Explored the efficacy and safety of S-1 + ramucirumab, achieved good OS.•PFS and ORR were also sufficient results.•Frequent grade 3/4 (≥15%) adverse events were neutropenia, anorexia and anaemia.

查看译文

关键词

Elderly patient,gastric cancer,S-1,Ramucirumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要